BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 17450472)

  • 1. CYP450 polymorphisms predict clinic outcomes to vinorelbine-based chemotherapy in patients with non-small-cell lung cancer.
    Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN
    Acta Oncol; 2007; 46(3):361-6. PubMed ID: 17450472
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MDR1 single nucleotide polymorphisms predict response to vinorelbine-based chemotherapy in patients with non-small cell lung cancer.
    Pan JH; Han JX; Wu JM; Sheng LJ; Huang HN; Yu QZ
    Respiration; 2008; 75(4):380-5. PubMed ID: 17851225
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cyclin D1 (CCND1) A870G gene polymorphism modulates smoking-induced lung cancer risk and response to platinum-based chemotherapy in non-small cell lung cancer (NSCLC) patients.
    Gautschi O; Hugli B; Ziegler A; Bigosch C; Bowers NL; Ratschiller D; Jermann M; Stahel RA; Heighway J; Betticher DC
    Lung Cancer; 2006 Mar; 51(3):303-11. PubMed ID: 16406195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. XPC gene intron 11 C/A polymorphism is a predictive biomarker for the sensitivity to NP chemotherapy in patients with non-small cell lung cancer.
    Zhu LB; Xu Q; Hong CY; Yue Z; Zhang Y; Ye HN; Yuan Y
    Anticancer Drugs; 2010 Aug; 21(7):669-73. PubMed ID: 20571354
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Polymorphisms in XRCC1 and XPG and response to platinum-based chemotherapy in advanced non-small cell lung cancer patients.
    Sun X; Li F; Sun N; Shukui Q; Baoan C; Jifeng F; Lu C; Zuhong L; Hongyan C; YuanDong C; Jiazhong J; Yingfeng Z
    Lung Cancer; 2009 Aug; 65(2):230-6. PubMed ID: 19157633
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [A study on the expression of CASP9 gene and its polymorphism distribution in non-small cell lung cancer].
    Lou Y; Fang CQ; Li JH
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Feb; 24(1):59-62. PubMed ID: 17285546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.
    Reck M; Macha HN; Del Barco S; Cornes P; Vaissière N; Morand M; Riggi M; Abratt R
    Lung Cancer; 2009 Jun; 64(3):319-25. PubMed ID: 19095327
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hsp27 may allow prediction of the response to single-agent vinorelbine chemotherapy in non-small cell lung cancer.
    Berrieman HK; Cawkwell L; O'Kane SL; Smith L; Lind MJ
    Oncol Rep; 2006 Jan; 15(1):283-6. PubMed ID: 16328069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prospective assessment of XPD Lys751Gln and XRCC1 Arg399Gln single nucleotide polymorphisms in lung cancer.
    Giachino DF; Ghio P; Regazzoni S; Mandrile G; Novello S; Selvaggi G; Gregori D; DeMarchi M; Scagliotti GV
    Clin Cancer Res; 2007 May; 13(10):2876-81. PubMed ID: 17504986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized phase III trial comparing bexarotene (L1069-49)/cisplatin/vinorelbine with cisplatin/vinorelbine in chemotherapy-naive patients with advanced or metastatic non-small-cell lung cancer: SPIRIT I.
    Ramlau R; Zatloukal P; Jassem J; Schwarzenberger P; Orlov SV; Gottfried M; Pereira JR; Temperley G; Negro-Vilar R; Rahal S; Zhang JK; Negro-Vilar A; Dziewanowska ZE
    J Clin Oncol; 2008 Apr; 26(11):1886-92. PubMed ID: 18398154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.
    Heist RS; Zhai R; Liu G; Zhou W; Lin X; Su L; Asomaning K; Lynch TJ; Wain JC; Christiani DC
    J Clin Oncol; 2008 Feb; 26(6):856-62. PubMed ID: 18281657
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vinorelbine and oxaliplatin in stage IV nonsmall cell lung cancer patients unfit for cisplatin: a single-center experience.
    Mir O; Alexandre J; Ropert S; Montheil V; Martin I; Durand JP; Goldwasser F
    Anticancer Drugs; 2009 Feb; 20(2):105-8. PubMed ID: 19209026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer.
    Wong M; Balleine RL; Blair EY; McLachlan AJ; Ackland SP; Garg MB; Evans S; Farlow D; Collins M; Rivory LP; Hoskins JM; Mann GJ; Clarke CL; Gurney H
    J Clin Oncol; 2006 Jun; 24(16):2448-55. PubMed ID: 16651648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cisplatin plus weekly vinorelbine versus cisplatin plus vinorelbine on days 1 and 8 in advanced non-small cell lung cancer: a prospective randomized phase III trial of the G.O.I.M. (Gruppo Oncologico Italia Meridionale).
    Gebbia V; Galetta D; Lorusso V; Caruso M; Verderame F; Pezzella G; Borsellino N; Durini E; Valenza R; Agostara B; Colucci G;
    Lung Cancer; 2008 Sep; 61(3):369-77. PubMed ID: 18308419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic polymorphism and gene expression of microsomal epoxide hydrolase in non-small cell lung cancer.
    Lin TS; Huang HH; Fan YH; Chiou SH; Chow KC
    Oncol Rep; 2007 Mar; 17(3):565-72. PubMed ID: 17273734
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of combination chemotherapy with mitomycin and vinorelbine for the treatment of advanced non-small cell lung cancer.
    Wibmer T; Kropf C; Merk T; Schumann C; Hombach V; Krüger S
    Lung Cancer; 2008 May; 60(2):231-9. PubMed ID: 18006111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II randomized study of vinorelbine alone or with cisplatin against chemo-naïve inoperable non-small cell lung cancer in the elderly.
    Chen YM; Perng RP; Shih JF; Whang-Peng J
    Lung Cancer; 2008 Aug; 61(2):214-9. PubMed ID: 18243407
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Polymorphisms in the FAS and FASL genes and survival of early stage non-small cell lung cancer.
    Park JY; Lee WK; Jung DK; Choi JE; Park TI; Lee EB; Cho S; Park JY; Cha SI; Kim CH; Kam S; Jung TH; Jheon S
    Clin Cancer Res; 2009 Mar; 15(5):1794-800. PubMed ID: 19240174
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The polymorphisms of TS and MTHFR predict survival of gastric cancer patients treated with fluorouracil-based adjuvant chemotherapy in Chinese population.
    Huang ZH; Hua D; Li LH
    Cancer Chemother Pharmacol; 2009 Apr; 63(5):911-8. PubMed ID: 18704422
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vinorelbine--a clinical review.
    Gregory RK; Smith IE
    Br J Cancer; 2000 Jun; 82(12):1907-13. PubMed ID: 10864196
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.